These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 15146368

  • 1. Applicability of the SHBG androgen sensitivity test in the differential diagnosis of 46,XY gonadal dysgenesis, true hermaphroditism, and androgen insensitivity syndrome.
    Krause A, Sinnecker GH, Hiort O, Thamm B, Hoepffner W.
    Exp Clin Endocrinol Diabetes; 2004 May; 112(5):236-40. PubMed ID: 15146368
    [Abstract] [Full Text] [Related]

  • 2. [A laboratory test for the detection of androgen resistance using sex hormone-binding globulin].
    Hampl R, Stárka L, Snajderová M, Lachman M, Kalvachová B.
    Vnitr Lek; 1992 Sep; 38(9):879-86. PubMed ID: 1481386
    [Abstract] [Full Text] [Related]

  • 3. Sex hormone-binding globulin response to the anabolic steroid stanozolol: evidence for its suitability as a biological androgen sensitivity test.
    Sinnecker G, Köhler S.
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1195-200. PubMed ID: 2723028
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of SHBG test for disclosure of insensitivity to androgens.
    Hampl R, Stárka L, Kalvachová B, Lachman M, Snajderová M, Lisá L, Zapletalová J, Hill M.
    Endocr Regul; 1993 Jun; 27(2):65-70. PubMed ID: 8003712
    [Abstract] [Full Text] [Related]

  • 5. Functional assessment and clinical classification of androgen sensitivity in patients with mutations of the androgen receptor gene. German Collaborative Intersex Study Group.
    Sinnecker GH, Hiort O, Nitsche EM, Holterhus PM, Kruse K.
    Eur J Pediatr; 1997 Jan; 156(1):7-14. PubMed ID: 9007482
    [Abstract] [Full Text] [Related]

  • 6. Prostate screening in patients with 46,XY disorders of sex development--is it necessary?
    Salmasi AH, Wisniewski AB, Novak TE, Gearhart JP, Migeon CJ, Lakshmanan Y.
    J Urol; 2008 Oct; 180(4):1422-5; discussion 1425-6. PubMed ID: 18710761
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Differentiating Swyer syndrome and complete androgen insensitivity syndrome: a diagnostic dilemma.
    Nunes E, Rodrigues C, Geraldes F, Aguas F.
    J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):e67-8. PubMed ID: 24119655
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Androgen insensitivity].
    Stárka L, Hampl R.
    Cas Lek Cesk; 1994 Jun 27; 133(13):387-90. PubMed ID: 8062328
    [Abstract] [Full Text] [Related]

  • 15. Plasma sex hormone-binding globulin rather than corticosteroid-binding globulin is a marker of insulin resistance in obese adult males.
    Lewis JG, Shand BI, Elder PA, Scott RS.
    Diabetes Obes Metab; 2004 Jul 27; 6(4):259-63. PubMed ID: 15171749
    [Abstract] [Full Text] [Related]

  • 16. Molecular analysis of the AR and SRD5A2 genes in patients with 46,XY disorders of sex development.
    Choi JH, Kim GH, Seo EJ, Kim KS, Kim SH, Yoo HW.
    J Pediatr Endocrinol Metab; 2008 Jun 27; 21(6):545-53. PubMed ID: 18717241
    [Abstract] [Full Text] [Related]

  • 17. Novel androgen receptor gene mutations in Australian patients with complete androgen insensitivity syndrome.
    MacLean HE, Ball EM, Rekaris G, Warne GL, Zajac JD.
    Hum Mutat; 2004 Mar 27; 23(3):287. PubMed ID: 14974091
    [Abstract] [Full Text] [Related]

  • 18. 46,XY disorders of sex development--the undermasculinised male with disorders of androgen action.
    Werner R, Grötsch H, Hiort O.
    Best Pract Res Clin Endocrinol Metab; 2010 Apr 27; 24(2):263-77. PubMed ID: 20541151
    [Abstract] [Full Text] [Related]

  • 19. Mutations in the amino-terminal domain of the human androgen receptor may be associated with partial androgen insensitivity and impaired transactivation in vitro.
    Holterhus PM, Werner R, Struve D, Hauffa BP, Schroeder C, Hiort O.
    Exp Clin Endocrinol Diabetes; 2005 Sep 27; 113(8):457-63. PubMed ID: 16151980
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.